Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium cantharidate is a derivative of the terpenoid toxin cantharidin, originally derived from blister beetles. It has been used in traditional Chinese medicine and investigated for its antitumor properties. Sodium cantharidate is primarily studied as an adjunct therapy in cancer treatment, particularly for non-small cell lung cancer (NSCLC) and primary liver cancer, where it may improve objective response rates and quality of life when combined with chemotherapy or other agents[2][1][4]. Its mechanism of action involves targeting rapidly proliferating cells such as cancer cells, potentially through inhibition of protein phosphatase activity or suppression of STAT3 signaling pathways[6][3]. The drug is not approved by the FDA for systemic use but has been widely used in clinical practice in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium cantharidate.